Pharmacogenomics in cardiovascular diseases

被引：19

作者：

Mukherjee, D

Topol, EJ

机构：

[1] Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA

[2] Univ Michigan, Div Cardiol, Ann Arbor, MI 48109 USA

来源：

PROGRESS IN CARDIOVASCULAR DISEASES | 2002年 / 44卷 / 06期

关键词：

D O I：

10.1053/pcad.2002.123467

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Considerable heterogeneity exists in the way individuals respond to medications, in terms of both efficacy and safety. Inherited differences in the absorption, metabolism, excretion, and target for drug therapy have important effects on drug efficacy and safety. Pharmacogenomics aims to discover new therapeutic targets and understand genetic polymorphisms that determine the safety and efficacy of medications. The goal of pharmacogenomics is customization of drug therapy with administration of a medication in an optimum dose that will be safe and effective with reduction in morbidity and mortality. Copyright 2002, Elsevier Science (USA). All rights reserved.

引用

页码：479 / 498

页数：20

共 139 条

[1] MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia [J].

Abbott, GW ;

Sesti, F ;

Splawski, I ;

Buck, ME ;

Lehmann, WH ;

Timothy, KW ;

Keating, MT ;

Goldstein, SAN .

CELL, 1999, 97 (02) :175-187

[2] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].

Aithal, GP ;

Day, CP ;

Kesteven, PJL ;

Daly, AK .

LANCET, 1999, 353 (9154) :717-719

[3] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].

ALTMAN, R ;

CARRERAS, L ;

DIAZ, R ;

FIGUEROA, E ;

PAOLASSO, E ;

PARODI, JC ;

CADE, JF ;

DONNAN, G ;

EADIE, MJ ;

GAVAGHAN, TP ;

OSULLIVAN, EF ;

PARKIN, D ;

RENNY, JTG ;

SILAGY, C ;

VINAZZER, H ;

ZEKERT, F ;

ADRIAENSEN, H ;

BERTRANDHARDY, JM ;

BRAN, M ;

DAVID, JL ;

DRICOT, J ;

LAVENNEPARDONGE, E ;

LIMET, R ;

LOWENTHAL, A ;

MORIAU, M ;

SCHAPIRA, S ;

SMETS, P ;

SYMOENS, J ;

VERHAEGHE, R ;

VERSTRAETE, M ;

ATALLAH, A ;

BARNETT, H ;

BATISTA, R ;

BLAKELY, J ;

CAIRNS, JA ;

COTE, R ;

CROUCH, J ;

EVANS, G ;

FINDLAY, JM ;

GENT, M ;

LANGLOIS, Y ;

LECLERC, J ;

NORRIS, J ;

PINEO, GF ;

POWERS, PJ ;

ROBERTS, R ;

SCHWARTZ, L ;

SICURELLA, J ;

TAYLOR, W ;

THEROUX, P .

BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100

[4]

Alves S, 1999, PHARMACOGENETICS, V9, P257

[5]

[Anonymous], 1998, NAT BIOTECHNOL, V16, P885

[6] INDICATIONS FOR FIBRINOLYTIC THERAPY IN SUSPECTED ACUTE MYOCARDIAL-INFARCTION - COLLABORATIVE OVERVIEW OF EARLY MORTALITY AND MAJOR MORBIDITY RESULTS FROM ALL RANDOMIZED TRIALS OF MORE THAN 1000 PATIENTS [J].

APPLEBY, P ;

BAIGENT, C ;

COLLINS, R ;

FLATHER, M ;

PARISH, S ;

PETO, R ;

BELL, P ;

HALLS, H ;

MEAD, G ;

DIAZ, R ;

PAOLASSO, E ;

PAVIOTTI, C ;

ROMERO, G ;

CAMPBELL, T ;

OROURKE, MF ;

THOMPSON, P ;

LESAFFRE, E ;

VANDEWERF, F ;

VERSTRAETE, M ;

ARMSTRONG, PW ;

CAIRNS, JA ;

MORAN, C ;

TURPIE, AG ;

YUSUF, S ;

GRANDE, P ;

HEIKKILA, J ;

KALA, R ;

BASSAND, JP ;

BOISSEL, JP ;

BROCHIER, M ;

LEIZOROVICZ, A ;

BRUGGEMANN, T ;

KARSCH, KR ;

KASPER, W ;

LAMMERTS, D ;

NEUHAUS, KL ;

MEYER, J ;

SCHRODER, R ;

VONESSEN, R ;

SARAN, RK ;

ARDISSINO, D ;

BONADUCE, D ;

BRUNELLI, C ;

CERNIGLIARO, C ;

FORESTI, A ;

FRANZOSI, MG ;

GUIDUCCI, D ;

MAGGIONI, A ;

MAGNANI, B ;

MATTIOLI, G .

LANCET, 1994, 343 (8893) :311-322

[7] CLINICAL OBSERVATIONS ON EFFECTS OF DEBRISOQUINE SULPHATE IN PATIENTS WITH HIGH BLOOD-PRESSURE [J].

ATHANASSIADIS, D ;

CRANSTON, WI ;

JUELJENS.BE ;

OLIVER, DO .

BMJ-BRITISH MEDICAL JOURNAL, 1966, 2 (5516) :732-+

[8]

Baba Y, 2000, Tanpakushitsu Kakusan Koso, V45, P76

[9] Association of hypertension with T594M mutation in β subunit of epithelial sodium channels in black people resident in London [J].

Baker, EH ;

Dong, YB ;

Sagnella, GA ;

Rothwell, M ;

Onipinla, AK ;

Markandu, ND ;

Cappuccio, FP ;

Cook, DG ;

Persu, A ;

Corvol, P ;

Jeunemaitre, X ;

Carter, ND ;

MacGregor, GA .

LANCET, 1998, 351 (9113) :1388-1392

[10]

BALANTGORGIA AE, 1989, THER DRUG MONIT, V11, P415

← 1 2 3 4 5 6 7 8 9 10 →